About the Authors

Iryna Dekhtiarenko

Contributed equally to this work with: Iryna Dekhtiarenko, Robert B. Ratts

Affiliation Department of Vaccinology, Helmholtz Centre for Infection Research, Braunschweig, Germany

Robert B. Ratts

Contributed equally to this work with: Iryna Dekhtiarenko, Robert B. Ratts

Affiliation TomegaVax Inc., Portland, Oregon, United States of America

Renata Blatnik

Affiliations Immunotherapy and prevention, German Cancer Research Center (DKFZ), Heidelberg, Germany, Molecular Vaccine Design, German Center for Infection Research (DZIF), Heidelberg, Germany

Lian N. Lee

Affiliation Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

Sonja Fischer

Affiliation Department of Vaccinology, Helmholtz Centre for Infection Research, Braunschweig, Germany

Lisa Borkner

Affiliation Department of Vaccinology, Helmholtz Centre for Infection Research, Braunschweig, Germany

Jennifer D. Oduro

Affiliation Department of Vaccinology, Helmholtz Centre for Infection Research, Braunschweig, Germany

Thomas F. Marandu

Affiliations Department of Vaccinology, Helmholtz Centre for Infection Research, Braunschweig, Germany, Dar es Salaam University College of Education, Dar es Salaam, Tanzania

Stephanie Hoppe

Affiliations Immunotherapy and prevention, German Cancer Research Center (DKFZ), Heidelberg, Germany, Molecular Vaccine Design, German Center for Infection Research (DZIF), Heidelberg, Germany

Zsolt Ruzsics

Affiliation Institute for Virology, University Medical Center Freiburg, Freiburg, Germany

Julia K. Sonnemann

Affiliation Department of Vaccinology, Helmholtz Centre for Infection Research, Braunschweig, Germany

Mandana Mansouri

Affiliation Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America

Christine Meyer

Affiliation TomegaVax Inc., Portland, Oregon, United States of America

Niels A. W. Lemmermann

Affiliation Institute for Virology and Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany

Rafaela Holtappels

Affiliation Institute for Virology and Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany

Ramon Arens

Affiliation Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands

Paul Klenerman

Affiliation Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

Klaus Früh

Affiliations TomegaVax Inc., Portland, Oregon, United States of America, Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America

Matthias J. Reddehase

Affiliation Institute for Virology and Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany

Angelika B. Riemer

Affiliations Immunotherapy and prevention, German Cancer Research Center (DKFZ), Heidelberg, Germany, Molecular Vaccine Design, German Center for Infection Research (DZIF), Heidelberg, Germany

Luka Cicin-Sain

luka.cicin-sain@helmholtz-hzi.de

Affiliations Department of Vaccinology, Helmholtz Centre for Infection Research, Braunschweig, Germany, German Center for Infection Research (DZIF), Partner site Hannover/Braunschweig, Germany, Institute for Virology, Medical School Hannover, Germany

Competing Interests

The authors declare the following competing financial interest: Oregon Health and Science University (OHSU) and KF have a significant financial interest in TomegaVax Inc., a company that may have a commercial interest in the results of this research and technology. LCS was a paid consultant of Tomegavax in 2015. This potential individual and institutional conflict of interest has been reviewed and managed by OHSU. RBR and CM have been employed by TomegaVax, Inc., a commercial company. The authors declare that there are no further financial interests.

Author Contributions

Conceptualization: ID RA PK KF MJR ABR LCS. Formal analysis: ID LCS. Funding acquisition: ABR LCS. Investigation: ID RBR RB LNL SF LB JDO TFM SH JKS. Methodology: ID RBR RB LNL ZR MM CM NAWL RH. Project administration: LCS. Resources: ZR. Supervision: PK KF ABR. Visualization: ID RBR LNL RB. Writing – original draft: ID LCS. Writing – review & editing: RBR RA PK KF MJR ABR LCS.